Optinose announced that it has signed an agreement with Kaleo for co-promotion of Optinose’s Xhance fluticasone propionate nasal spray for the treatment of nasal polyps. Xhance was approved by the FDA for that indication in September 2017. The agreement calls for Kaleo to promote the nasal spray to a group of almost 6,000 healthcare providers in the US.
Optinose Chief Commercial Officer Vic Clavelli said, “We are excited to partner with Kaleo and leverage the strong relationships they have built with physicians in our target audience. This co-promotion partnership will build upon that strength and help us grow our target audience’s appreciation for all Xhance has to offer by efficiently broadening and deepening our promotional reach. I am confident that the Kaleo sales team will complement and amplify the efforts of the Optinose team starting in the fourth quarter of this year.”
Kaleo General Manager of Allergy and Pediatrics Omar Khalil commented, “Our team is pleased to collaborate with Optinose on the promotion of Xhance. The deep relationships we have developed over the years with allergists makes Kaleo a natural fit for this innovative product that serves the needs of patients with this condition.”
Read the Optinose press release.
